KTTA Stock Forecast & Price Target

Pasithea Therapeutics is attractive fundamentally because PAS-004 targets the RAS/MAPK pathway with a differentiated macrocyclic MEK-inhibitor design, aiming to overcome the resistance, toxicity, and limited durability that constrain older MEK drugs. The program has meaningful regulatory validation through Orphan Drug, Fast Track, and Rare Pediatric Disease Designation, which also creates potential Priority Review Voucher value that has been cited at $150 million to $250 million, while early Phase 1/1b data and the advanced cancer study suggest safety, tolerability, and pharmacologic breadth. The recent extension of treatment duration to up to 18 months and added MRI/CN measurements should deepen the efficacy dataset, improve durability assessment, and strengthen optionality across NF1-PN, NF1-CN, and broader oncology markets.

Pasithea Therapeutics is a speculative biotechnology company whose value depends almost entirely on the success of its early-stage pipeline, including PAS-004, PAS-003, and PAS-001, across highly uncertain CNS disorders, RASopathies, and cancers. The cited risks of failed or inconclusive clinical trials, inadequate funding to advance drugs through development, and dilutive capital raises underscore a fragile financing profile and a business model that has yet to demonstrate durable clinical or commercial validation. With a single reportable segment centered on research and development rather than recurring product revenue, the company remains exposed to binary trial outcomes and shareholder dilution, which supports a negative outlook.